期刊文献+

血管紧张素Ⅱ1型受体拮抗剂对糖尿病肾病大鼠肾小球内12-脂氧合酶活性及P钙黏蛋白表达的影响 被引量:10

Effect of angiotensin II type 1 receptor blocker on the 12-lipoxygenase activity and P-cadherin expression in type 2 diabetic rat glomeruli
原文传递
导出
摘要 目的探讨血管紧张素Ⅱ(AngⅡ)1型受体拮抗剂(ARB)对2型糖尿病肾病(DN)大鼠肾小球内12.脂氧合酶(12-LO)活性及P钙黏蛋白(P.cadherin)表达的影响。方法用10^-7 mol/L Ang II处理足细胞24h。采用皮下包埋的微型渗透泵给雄性SD大鼠分别持续恒速注入12-LO代谢产物12羟二十烷四烯酸[12(S)-HETE,1mg·kg-1·d-1]和AngⅡ(400ng·kg-1·min-1)1周和2周。使用高脂饮食结合小剂量链脲菌素(STZ)诱导2型糖尿病模型,大鼠模型成功后随机分为2组:DN组和ARB(5mg·kg-1·d-1洛沙坦)组。以规律正常饮食大鼠作为对照组。6周后处死大鼠,收集尿、血液,提取肾脏,用系列过筛方法分离肾小球。采用ELISA、RT-PCR和Western印迹法分别检测相关指标。结果Ang II的直接刺激可以诱导足细胞及肾小球内12(s).HETE含量增高(P〈0.01)。12(S)-HETE刺激使大鼠肾小球内AngII含量增高(P〈0.01)。与对照组比较,DN组血糖(P〈0.01)、肾质量/体质量(P〈0.01)和24h尿白蛋白明显增高(P〈0.01),但洛沙坦治疗后尿白蛋白(P〈0.05)、肾质量/体质量(P〈0.05)明显低于DN组。与对照组比较,DN组肾小球内12(s).HETE含量明显增高(P〈0.01),P.cadherinmRNA和蛋白表达明显降低(P〈0.01),但洛沙坦治疗后肾小球内12(s)-HETE含量明显低于DN组(P〈0.05),P—cadherinmRNA和蛋白表达明显高于DN组(P〈0.05)。结论AngII通过激活12-LO诱导肾小球内P.cadherin的表达下调。ARB通过抑制12-LO活性而上调DN肾小球内P—cadherin表达,从而延缓DN的进展。 Objective To investigate the effect of angiotensin II (Ang II) type 1 receptor blocker (ARB) on 12-1ipoxygenase (12-LO) activity and P-cadherin expression in type 2 diabetic rat glomeruli. Methods Podocytes were stimulated by 10^-7 mol/L Ang II for 24 hours. 12(S)-HETE (1 mg. kg-1. d-1) and Ang II (400 ng. kg-1. min -1) were infused to rats by osmotic mini-pump for 1 week and 2 weeks respectively. Rats fed with high fat diet received low dose streptozotocin (STZ) to make type 2 diabetes and divided into 2 groups: low dose STZ (DN group), low dose STZ + ARB treatment (Losartan group). Rats fed with regular chow were used as control group. All the rats were sacrificed after 6 weeks. Urine, blood, kidney cortical tissue and isolated glomeruli by sieving method were collected at the end of study respectively. ELISA, RT-PCR and Western blotting for related target were performed respectively, Results Ang II increased 12(S)-HETE levels in podocytes and glomeruli (all P 〈 0.01). Ang II levels in the glomeruli were significantly increased by 12(S)-HETE stimulation (P 〈 0.01). Blood glucose, kidney/body weight and 24 hour urinary protein were increased in DN group compared with that in control group (all P 〈 0.01). However, urine protein, Kidney/body weight were decreased in Losartan group compared with DN group (all P 〈 0.05). Increment of 12(S)-HETE content and decrement of P-cadherin expression were observed in DN glomeruli compared with that in control group(all P 〈 0.01). These abnormalities were prevented by administration of the losartan (all P 〈 0.05). Conclusions Ang II can down-regulate glomerular P-cadherin expression via activation of 12-LO. ARB can ameliorate the progression of DN via up- regulation of glomerular P- eadherin through inhibition of 12-LO activation in type 2 DN rats.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2013年第3期210-215,共6页 Chinese Journal of Nephrology
基金 基金项目:国家自然科学基金(81070578,81270809) 吉林大学科学前沿与交叉学科创新项目(200903056)
关键词 血管紧张素Ⅱ 1型受体拮抗剂 糖尿病肾病 脂氧合酶 血管紧张素Ⅱ 钙黏着糖蛋白类 Angiotensin II type 1 receptor blockers Diabetic nephropathies Lipoxygenase Angiotensin II Cadherin
  • 相关文献

参考文献15

  • 1Yuan H, Lanting L, Xu ZG, et al. Effects of cholesterol - laggedsmall interfering RNAs targeting 12/15 - lipoxygenase* onparameters of (lial)etic nephropathy in a mouse model of type 1(liabetes. Ain J Physiol Renal Physiol, 2(K)8. 295: F605-K617.
  • 2Kang SW, Natarajan R, Slmhcd A, et al. Role of 12 -lipoxygenase in the stimulalion of p38 mitogen - activatedprotein kinase and collagen alpha5 (IV) in experimentaldiabetic nephmpatliy and in glucose - stimulated pmlocvtes. JAm Soc Nephrol, 2003,14: 3178-3187.
  • 3Reddy MA, Adler SG, Kim YS, et al. Interaction of MAPK and12 - lipoxygenase pathways in growth and matrix proteinexpression in mesangial cells. Am J Physiol Renal Physiol,2002,283: F985-F994.
  • 4Kim YS, Xu ZG, Reddy MA, et al. Novel interactions betweenTGF - (beta) 1 actions and the 12/15 - lipoxygenase pathway inmesangial cells, J Am Soc Nephrol, 2005, 16: 352-362.
  • 5Doublier S, Salvidio G, Lupia E, et al. Nephrin expression isreduced in human diabetic nephropathy: evidence for adistinct role for glycated albumin and angiotensin D . Diabetes,2003,52: 1023-1030.
  • 6Liu G, Kaw B, Kurfis J, et al. Nephl and nephrin interactionin the slit diaphragm is important determinant of glomerularpermeability. J Clin Invest, 2003, 112: 209-221.
  • 7Xu ZG, Ryu DR, Yoo TH, et al. P - Cadherin is decreased indiabetic glomeruli and in glucose - stimulated podocytes in vivoand in vitro studies. Nephrol Dial Transplant, 2005,20: 524 -531.
  • 8Guo QY, Miao LN, Xu ZG, et al. Role of 12-lipoxygenase indecreasing P - cadherin and increasing angiotensin H type 1receptor expression according to glomerular sizes in type 2diabetic rats. Am J Physiol Endocrinol Metab, 2011, 300: E708-E716.
  • 9Mundel P, Reiser J, Zuniga Mejfa Borja A, et al.Rearrangements of the cytoskeleton and cell contacts induceprocess formation during differentiation of conditionallyimmortalized mouse podocyte cell lines. Exp Cell Res, 1997,236: 248-258.
  • 10Lin KY, Ito A, Asagami T,et al. Impaired nitric oxidesynthase pathway in diabetes mellitus: role of asymmetricdimethylarginine and dimethylarginine dimethylaminohydrolase.Circulation, 2002, 106: 987-992.

同被引文献77

  • 1傅明捷,黄萍,王艳,等.糖尿病肾病患者蛋白尿与C反应蛋白、肿瘤坏死因子-α和白介素-6水平关系的临床研究[J].中国医药导报,2013,10(15):89-90.
  • 2Gariani K, de Seigneux S, Pechbre- Bertschi A, et al. Diabetic nephropathy: an update [J]. Rev Med Suisse, 2012, 8 (330): 473 - 479.
  • 3Ando K, Haneda M, ho S, et al. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study ( J - FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria[ J]. Cardiovasc Drugs Ther,2011,25 (4) :341 - 347.
  • 4Suzuki T, Nakao T, Harada S, etal. Results of kidney transplanta tion for diabetic nephropathy: a single center experience [J]. Transplant Proc,2014,46(2) :464.
  • 5Arora MK,Singh UK. Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Diabetic Nephropathy[J]. Curr Drug Targets, 2014,5(2) :885.
  • 6傅明捷,黄萍,王艳,等.糖尿病肾病患者蛋白尿与C反应蛋白、肿瘤坏死因子-和白介素-6水平关系的临床研究[J].中国医药导报,2013,10(15):89-90.
  • 7Gariani K,de Seigneux S,Pechbre-Bertschi A,et al.Diabetic nephropathy:an update[J].Rev Med Suisse,2012,8(330):473-479.
  • 8Ando K,Haneda M,Ito S,et al.Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG):evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria[J].Cardiovasc Drugs Ther,2011,25(4):341-347.
  • 9叶春芳,李树民,王晓丽,陈冬.糖尿病肾病合并高血压患者血清转化生长因子及相关指标的变化[J].江苏医药,2010,36(9):1035-1037. 被引量:4
  • 10张路霞,王海燕.从流行病学的角度探讨我国糖尿病肾病的发病趋势及对策[J].中华内科杂志,2010,49(9):804-805. 被引量:112

引证文献10

二级引证文献75

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部